Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Account Payables: 2023-2025

Historic Change in Account Payables for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to $1.2 million.

  • CG Oncology's Change in Account Payables rose 395.66% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 92.96%. This contributed to the annual value of $3.3 million for FY2024, which is 62.77% up from last year.
  • As of Q3 2025, CG Oncology's Change in Account Payables stood at $1.2 million, which was up 211.42% from $394,000 recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Change in Account Payables ranged from a high of $2.4 million in Q4 2024 and a low of -$415,000 during Q3 2024.
  • Moreover, its 3-year median value for Change in Account Payables was $394,000 (2025), whereas its average is $647,455.
  • Within the past 5 years, the most significant YoY rise in CG Oncology's Change in Account Payables was 15,844.44% (2024), while the steepest drop was 442.86% (2024).
  • Quarterly analysis of 3 years shows CG Oncology's Change in Account Payables stood at $1.4 million in 2023, then surged by 76.63% to $2.4 million in 2024, then surged by 395.66% to $1.2 million in 2025.
  • Its Change in Account Payables was $1.2 million in Q3 2025, compared to $394,000 in Q2 2025 and $214,000 in Q1 2025.